In the N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN) model, MIF accelerates bladder cancer by promoting cell proliferation and angiogenesis, so MIF inhibitors may be a helpful treatment in the field of this disease [139]. This evidence concerns the gene MIF and urinary bladder cancer.